Targets of emerging therapies for viral hepatitis B and C

Yerly, Daniel; Di Giammarino, Loriana; Bihl, Florian; Cerny, Andreas (2006). Targets of emerging therapies for viral hepatitis B and C. Expert opinion on therapeutic targets, 10(6), pp. 833-50. London: Informa Healthcare 10.1517/14728222.10.6.833

Full text not available from this repository.

Viral hepatitis B and C, structurally two completely different viruses, commonly infect human hepatocytes and cause similar clinical manifestations. Since their discovery, IFN has been a pillar in the treatment. However, because of the different natures of the viruses, therapeutic approaches diverge and new treatment targets are tailored specifically for each virus. Herein, the authors analyse therapeutic approaches for hepatitis B virus (HBV) and hepatitis C virus (HCV) and focus on emerging concepts that are under clinical evaluation. In particular, promising viral inhibitors for HBV and HCV are reviewed and the current status of research for gene therapy for HCV is described. Immune therapy is a fast-moving field with fascinating results which include therapeutic vaccines and toll-like receptor agonists that could improve tomorrow's treatment approaches.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Service Sector > Institute of Clinical Pharmacology and Visceral Research [discontinued]
UniBE Contributor:	Cerny, Andreas
ISSN:	1472-8222
ISBN:	17105371
Publisher:	Informa Healthcare
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:45
Last Modified:	05 Dec 2022 14:14
Publisher DOI:	10.1517/14728222.10.6.833
PubMed ID:	17105371
Web of Science ID:	000242273500007
URI:	https://boris.unibe.ch/id/eprint/18578 (FactScience: 770)